For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg
Other Name: Cytoxan
Beginning on Day -3 pre-transplant maintaining a level of >200 ng/mL. CSA dosing will be monitored and altered as clinically appropriate by Pharm D or physician, and discontinue at approximately day + 180 post-transplant.
Other Name: CSA
25 mg/m2/day intravenous as a 1 hour infusion for consecutive 3 days pre-transplant, total dose 75 mg/m2
Other Name: Fludara
Drug: mycophenolate mofetil
Beginning on day -3, use intravenous route between days -3 and +5, followed by oral administration on Day +6 through +30, if tolerated. 15mg/kg/dose for patients <40 kg, 3 gm/day for patients >40 kg.
Other Name: MMF
Radiation: total marrow irradiation
Dose escalating schedule per Cohort (TMI: 300 cGy) once daily.
Other Name: TMI
Procedure: umbilical cord blood transplantation
product will be infused via intravenous drip on Day 0 according to current University of Minnesota guidelines for Umbilical Cord Blood Grafts
umbilical cord blood
allogeneic hematopoietic stem cell transplantation
Biological: Granulocyte colony-stimulating factor
5 mcg/kg/day intravenous or subcutaneous based on body weight beginning on Day +1 after umbilical cord blood infusion until absolute neutrophil count exceeds 2.5 x 10^9/L for 3 consecutive days.
Other Name: G-CSF
Biological: HLA-matched related donor bone marrow
Related donor bone marrow or mobilized stem cells will be collected (target cell dose 5x10^8 nucleated cells/kg recipient weight, minimum 3x10^8 nucleated cells/kg recipient weight) and infused without processing on day 0 according to University of Minnesota Blood and Marrow Transplant Program guidelines.
Other Name: mobilized peripheral blood stem cells